• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Charles River Laboratories Intl (NY: CRL )

    208.41 -1.06 (-0.51%)
    Official Closing Price Updated: 4:10 PM EDT, Jun 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 396,622
    Open 208.23
    Bid (Size) 83.24 (2)
    Ask (Size) 208.53 (1)
    Prev. Close 209.47
    Today's Range 207.02 - 209.06
    52wk Range 161.65 - 275.00
    Shares Outstanding 50,396,622
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
    From Charles River Laboratories International, Inc.
    Via Business Wire

    Performance

    YTD
    -11.03%
    -11.03%
    1 Month
    -5.96%
    -5.96%
    3 Month
    -20.49%
    -20.49%
    6 Month
    -8.63%
    -8.63%
    1 Year
    -0.53%
    -0.53%

    More News

    Read More
    The Analyst Verdict: Charles River In The Eyes Of 4 Experts
    Via Benzinga
    The Analyst Landscape: 7 Takes On Charles River
    Via Benzinga
    Evaluating Charles River: Insights From 7 Financial Analysts
    Via Benzinga
    Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories to Present at William Blair and Jefferies Conferences
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
    From Charles River Laboratories International, Inc.
    Via Business Wire
    CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Charles River Laboratories Announces First-Quarter 2024 Results
    From Charles River Laboratories International, Inc.
    Via Business Wire
    The 7 Best Growth Stocks to Buy in May 2024
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River to Perform Plasmid Production for Ship of Theseus
    From Charles River Laboratories International, Inc.
    Via Business Wire
    CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Laboratories Publishes 2023 Corporate Citizenship Report
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
    From Charles River Laboratories International, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.